Bleomycin-induced pulmonary toxicity in chemotherapy for testicular cancer

Bibliography

• UMEZAWA H, MAEDA K, TAKEUCHI T, OKAMI Y: New antibiotics, bleomycin A and B. Antibiot. (Tokyo) (1966) 19:200–209.
   PubMed Web of Science ®Google Scholar
• UMEZAWA H: Chemistry and mechanisms of action of bleomycin. Fed. Proc. (1974) 33:2296–2302.
   PubMedGoogle Scholar
• ICHIKAWA T, NAKANO I, HIROKAWA I: Bleomycin treatment of the tumors of penis and scrotum. J Ural. (1969) 102:699–707.
   PubMed Web of Science ®Google Scholar
• YAGODA A, MUKHERJI B, YOUNG C et al.: Bleomycin, an antitumor antibiotic. Ann. Intern. Med. (1972) 77:861–870.
   PubMed Web of Science ®Google Scholar
• PRESTAYKO AW, CROOKE ST: Clinical pharmacology of bleomycin. In: Bleomycin: Current status and new developments. Carter SK, Urnezawa H, Crooke ST (Eds), Academic Press, Inc., New York (1978) 117–130.
   Google Scholar
• UMEZAWA H, TAKEUCHI T, HOSHI S, SAWA T, ISHIZUKA M: Studies on the mechanism of antitumor effect of bleomycin of squamous cell carcinoma. Antibiot. (1972) 25:409–420.
   Google Scholar
• ONUMA T, HOLLAND JF, MASUDA H, WALIGUNDA JA, GOLDBERG GA: Microbiological assay of bleomycin: inactivation, tissue distribution, and clearance. Cancer (1974) 33:1230–1238.
   PubMed Web of Science ®Google Scholar
• SANTRACH PJ, ASKIN FB, WELLS RJ, AZIZKHAN AG, MERTEN DF: Nodular form of bleomycin-related pulmonary injury in patients with osteogenic sarcoma. Cancer (1989) 64:806–811.
   PubMed Web of Science ®Google Scholar
• YOUSEM S, LIFSON J, COLBY T: Chemotherapy-induced eosinophilic pneumonia: relation to bleomycin. Chest (1985) 88:103–106.
   PubMed Web of Science ®Google Scholar
• BLUM RH, CARTER SK, AGRE K: A clinical review of bleomycin - a new antineoplastic agent. Cancer (1973) 31:903–913.
   PubMed Web of Science ®Google Scholar
• BAUER KA, SKARIN AT, BALIKIAN JP, GARNICK MB, ROSENTHAL DS, CANELLOS GP: Pulmonary complications association with combination chemotherapy programs containing bleomycin. Am. J Med. (1983) 74:557–563.
   PubMed Web of Science ®Google Scholar
• WHITE DA, STOVER DE: Severe bleomycin-induced pneumonitis. Clinical features and response to corticosteroids. Chest (1984) 86:723–728.
   Google Scholar
• JULES-ELYSEE K, WHITE DA: Bleomycin-induced pulmonary toxicity. Clin. Chest Med. (1990) 11:1–20.
   PubMed Web of Science ®Google Scholar
• GINSBERG S, COMIS RL: The pulmonary toxicity of antineoplastic agents. Semin. Oncol (1982) 9:34–51.
   PubMed Web of Science ®Google Scholar
• SIMPSON AB, PAUL J, GRAHAM J, KAYE SB: Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours. Br .j Cancer (1998) 78:1061–1066.
   PubMed Web of Science ®Google Scholar
• CROOKE ST, COMIS RL, EINHORN LH, STRONG JE, BROUGHTON A, PRESTAYKO AW: Effects of variations in renal function on the clinical pharmacology of bleomycin administered as an i.v. bolus. Cancer Treat Rep. (1977) 61: 1631-1636.
   Google Scholar
• VAN BARNEVELD PW, SLEIJFER DT, VAN DER MARK TW et al.: Influence of platinum-induced renal toxicity on bleomycin-induced pulmonary toxicity in patients with disseminated testicular carcinoma. Onco/ogy (1984) 41:4–7.
   Google Scholar
• HALL SW STRONG JE, BROUGHTON A, FRAZIER ML, BENJAMIN RS: Bleomycin clinical pharmacology by radioimmunoassay. Cancer Chenzother. Pharmacol (1982) 8:22–25.
   Google Scholar
• KAWAI K, HINOTSU S, TOMOBE M, AKAZA H: Serum creatinine level during chemotherapy for testicular cancer as a possible predictor of bleomycin-induced pulmonary toxicity. Jpn. j Clin. Oncol (1998) 28:546–550.
   PubMed Web of Science ®Google Scholar
• O'SULLIVAN JM, HUDDART RA, NORMAN AR, NICHOLLS J, DEARNALEY DP, HORWICH A: Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann. Oncol (2003) 14:91–96.
   PubMed Web of Science ®Google Scholar
• GOLDINER PL, CARLON GC, CVITKOVIC E, SCHWEIZER O, HOWLAND WS: Factors influencing post-operative morbidity and mortality in patients treated with bleomycin. Br. Med .j (1978) 1:1664–1667.
   PubMed Web of Science ®Google Scholar
• HULBERT JC, GROSSMAN JE, CUMMINGS KB: Risk factors of anesthesia and surgery in bleomycin-treated patients. J. Urol. (1983) 130:163–164.
   PubMed Web of Science ®Google Scholar
• INGRASSIA TS III, RYU JH, TRASTEK VF, ROSENOW EC III: Oxygen-exacerbated bleomycin pulmonary toxicity. Mayo Clin. Proc. (1991) 66:173–178.
   PubMed Web of Science ®Google Scholar
• DONAT SM, LEVY DA: Bleomycin-associated pulmonary toxicity: is perioperative oxygen restriction necessary? J. Urol. (1998) 160:1347–1352.
   Web of Science ®Google Scholar
• TRYKA AF, SKORNIK WA, GOLDLESKI JJ, BRAIN JD: Potentiation of bleomycin-induced lung injury by exposure to 70% oxygen. Morphologic assessment. Am. Rev. Respir. Dis. (1982) 126:1074–1076.
   PubMed Web of Science ®Google Scholar
• MATTHEWS JH: Pulmonary toxicity ofABVD chemotherapy and G-CSF in Hodgkin's disease: possible synergy. Lancet (1993) 342:988. Letter.
   Google Scholar
• LEI KIK, LEUNG WT, JOHNSON PJ: Serious pulmonary complications in patients receiving recombinant granulocyte colony-stimulating factor during BACOP chemotherapy for aggressive non-Hodgkin's lymphoma. Br. J. Cancer (1994) 70:1009–1013.
   PubMed Web of Science ®Google Scholar
• DIRIX L, SCHRIJVERS D, DRUWE P, VAN DEN BRANDE J, VERHOEVEN D, VAN OOSTEROM AT: Pulmonary toxicity and bleomycin. Lancet (1994) 344:56. Letter.
   Google Scholar
• SAXMAN SB, NICHOLS CR, EINHORN LH: Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony-stimulating factor. Chest (1997) 111:657–660.
   PubMed Web of Science ®Google Scholar
• SAMUELS ML, JOHNSON DE, HOLOYE PY, LANZOTTI VJ: Large dose bleomycin pulmonary toxicity. A possible role of prior radiotherapy. JAMA (1976) 235:1117–1120.
   Google Scholar
• LOWER EE, STROHOFER S, BAUGHMAN RP: Bleomycin causes alveolar macrophages from cigarette smokers to release hydrogen peroxide. Am. J. Med. Sci. (1988) 295:193–197.
   PubMed Web of Science ®Google Scholar
• VAN BARNEVELD PW, VAN DER MARK TW; SLEIFER DT et al.: Predictive factors for bleomycin-induced pneumonitis. Am. Rev. Respir. Dis. (1984) 130:1078–1081.
   PubMedGoogle Scholar
• COOPER JA Jr, WHITE DA, MATTHAY RA: Drug-induced pulmonary disease. Part 1. Cytotoxic drugs. Am. Rev. Respir. Dis. (1986) 133:321–340.
   Google Scholar
• BATIST G, ANDREWS JL Jr: Pulmonary toxicity of antineoplastic drugs. JAMA (1981) 246:1449–1153.
   PubMed Web of Science ®Google Scholar
• WHITE DA, SCHWARTZBERG LS, KRIS MG, BOSL GJ: Acute chest pain syndrome during bleomycin infusions. Cancer (1987) 59:1582–1585.
   PubMed Web of Science ®Google Scholar
• VAN BARNEVELD PW, SLEIJFER DT, VAN DER MARK TW et al.: Natural course of bleomycin-induced pneumonitis: a follow-up study. Am. Rev. Respir. Dis. (1987) 135:48–51.
   PubMedGoogle Scholar
• BALIKIAN JP, JOCHELSON MS, BAUER KA et al.: Pulmonary complications of chemotherapy regimens containing bleomycin. Am. J Roentgenol. (1982) 139:455–461.
   PubMed Web of Science ®Google Scholar
• MCCREA ES, DIACONIS JN, WADE JC, JOHNSTON CA: Bleomycin toxicity simulating metastatic nodules to the lungs. Cancer (1981) 48:1096–1100.
   PubMed Web of Science ®Google Scholar
• DINEEN MK, ENGLANDER LS, HUBEN RP: Bleomycin-induced nodular pulmonary fibrosis masquerading as metastatic testicular cancer. J. Urol. (1986) 136:473–475.
   PubMed Web of Science ®Google Scholar
• BELLAMY EA, HUSBAND JE, BLAQUIERE RM, LAW MR: Bleomycin-related lung damage: CT evidence. Radiology (1985) 156:155–158.
   PubMed Web of Science ®Google Scholar
• ROSSI SE, ERASMUS FF, MCADAMS P, SPOM TA, GOODMAN PC: Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics (2000) 20:1245–1259.
   PubMed Web of Science ®Google Scholar
• COMIS RL: Detecting bleomycin pulmonary toxicity: a continued conundrum. j Gun. OncoL (1990) 8:765–767.
   Web of Science ®Google Scholar
• HIRSCH A, VANDER ELS N, STRAUS DJ et al.: Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease. j Gun. Oncol. (1996) 14:1297–1305.
   Web of Science ®Google Scholar
• SLEIJFER S, VAN DER MARK TW KOOPS HS, MULDER NH: Decrease in pulmonary function during bleomycin-containing combination chemotherapy for testicular cancer: not only a bleomycin effect. Br. J. Cancer (1995) 71:120–123.
   PubMed Web of Science ®Google Scholar
• •A complete evaluation of pulmonary function tests in chemotherapy for testicular cancer.
   Google Scholar
• WOLKOWICZ J, STURGEON J, RAWJI M, CHAN CK: Bleomycin-induced pulmonary function abnormalities. Chest (1992) 101:97–101.
   PubMed Web of Science ®Google Scholar
• HIGA GM, ALKHOURI N, AUBER ML: Elevation of the erythrocyte sedimentation rate precedes exacerbation of bleomycin-induced pulmonary toxicity: report of two cases and review of the literature. Pharmacotherapy (1997) 17:1315–1321.
   PubMed Web of Science ®Google Scholar
• EINHORN LH: Curing metastatic testicularcancer. Proc. Natl. Acad. Sci. USA (2002) 99:4592–4595.
   PubMed Web of Science ®Google Scholar
• •A thorough review on chemotherapy for testicular cancer.
   Google Scholar
• WILLIAMS SD, BIRCH R, EINHORN LH, IRWIN L, GRECO FA, LOEHRER PJ: Treatment of disseminated germ-cell tumors with capsulation, bleomycin, and either vinblastine or etoposide. N Engl. J. Med. (1987) 316:1435–1440.
   PubMed Web of Science ®Google Scholar
• FOSSA SD, KAYE SB, MEAD GM et al.: Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. j Gun. Oncol. (1998) 16:716–724.
   Google Scholar
• LOEHRER P, JOHNSON D, ELSON P, EINHORN LH, TRUMP D: Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J. Clin. Oncol. (1995) 13:470–476.
   PubMed Web of Science ®Google Scholar
• DE WIT R, STOTER G, KAYE SB et al.:Importance of bleomycin in combination chemotherapy for good-prognosis testicular non-seminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Gun. Oncol. (1997) 15:1837–1843.
   Web of Science ®Google Scholar
• TONER GC, STOCKLER MR, BOYER MJ et al.: Comparison of two standard chemotherapy regimens for good prognosis germ-cell tumours: a randomized trial. Lancet (2001) 357:739–745.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Gun. Oncol (1997) 15:594–603.
   Web of Science ®Google Scholar
• •Extremely useful guideline for prognostication of germ cell tumours.
   Google Scholar
• BAJORIN DF, BOSL GJ: Bleomycin in germ cell tumor therapy: not all regimens are created equal. Clin. Oncol (1997) 15:1717–1719.
   Web of Science ®Google Scholar
• CULINE S, KERBRAT P, BOUZY J et al.:Are 3 cycles of bleomycin, etoposide and cisplatin (3BEP) or 4 cycles of etoposide and cisplatin (4EP) equivalent regimens for patients with good-risk metastatic non-seminomatous germ cell tumours? Preliminary results of a randomized trial. Proc. Am. Soc. Clin. Oncol (1999) 18:A1188. Abstract.
   Google Scholar
• NICHOLS CR, CATALANO PJ, CRAWFORD ED, VOGELZANG NJ, EINHORN LH, LOEHRER PJ: Randomized comparisons of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ-cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. j Gun. Oncol (1998) 16:1287–1293.
   Web of Science ®Google Scholar
• JENSEN JL, GOEL R, VENNER PM: The effect of corticosteroid administration on bleomycin lung toxicity. Cancer (1990) 65:1291–1297.
   PubMed Web of Science ®Google Scholar
• JONES AW: Bleomycin lung damage: the pathology and nature of the lesion. Br. J. Dis. Chest (1978) 72:321–326.
   PubMedGoogle Scholar
• LUURSEMA PB, STAR-KROESEN MA, VAN DER MARK TW, SLEYFER DT, KOOPS HS, PESET R: Bleomycin-induced changes in the carbon monoxide transfer factor of the lungs and its components. Am. Rev. Respir. Dis. (1983) 128:880–883.
   PubMed Web of Science ®Google Scholar
• CHANDLER DB, HYDE DM, GIRT SN: Morphometric estimates of infiltrative cellular changes during the development of bleomycin-induced pulmonary fibrosis in hamsters. Am. J. Pathol (1983) 112:170–177.
   PubMed Web of Science ®Google Scholar
• THRALL RS, BARTON RW, D'AMATO DA, SULAVIK SB: Differential cellular analysis of bronchoalveolar lavage fluid obtained at various stages during the development of bleomycin-induced pulmonary fibrosis in the rat. Am. Rev. Respir. Dis. (1982) 126:488–492.
   PubMed Web of Science ®Google Scholar
• ZHU J, COHEN DA, GOUD SN, KAPLAN AM: Contribution of T lymphocytes to the development of bleomycin-induced pulmonary fibrosis. Ann. IVY Acad. Sci. (1996) 796:194–204.
   PubMed Web of Science ®Google Scholar
• SHARMA SK, MACLEAN JA, PINTO C, KRADIN RL: The effect of an anti-CD3 monoclonal antibody on bleomycin-induced lyniphokine production and lung injury. Am. J Respir. Grit. Care Med. (1996) 154:193–200.
   PubMed Web of Science ®Google Scholar
• HELENE M, LAKE-BULLOCK V, ZHU J,HAO H, COHEN DJ, KAPLAN AM: T cell independence of bleomycin-induced pulmonary fibrosis. J Leukoc. Biol. (1999) 65:187–195.
   PubMed Web of Science ®Google Scholar
• ASO Y, YONEDA Y, KIKKAWA Y: Morphological and biochemical study of pulmonary changes induced by bleomycin in mice. Lab. Invest. (1976) 35:558–568.
   PubMed Web of Science ®Google Scholar
• ISHIDA R, TAKAHASHI T: Increased DNA chain breakage by combined action of bleomycin and superoxide radical. Biochem. Biophys. Res. Commun. (1975) 66:1432–1438.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM ML, RINGROSE PS, LOKESH BR: Bleomycin cytotoxicity is prevented by superoxide dismutase in vitro. Cancer Lett. (1983) 21:149–153.
   PubMed Web of Science ®Google Scholar
• HAGIMOTO N, KUWANO K, NOMOTO Y, KUNITAKE R, HARA N: Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice. Am. J. Respir. Cell Mal (1997) 16:91–101.
   PubMed Web of Science ®Google Scholar
• KUWANO K, HAGIMOTO N, KAWASAKI M: Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J. Clin. Invest. (1999) 104:13–19.
   PubMed Web of Science ®Google Scholar
• SEINO K, IWABUCHI K, KAYAGAKI N et al.: Cutting edge: chemotactic activity of soluble Fas ligand against phagocytes. J. Immund (1998) 161:4484–4488.
   PubMed Web of Science ®Google Scholar
• COOPER JAD: Pulmonary fibrosis: pathways are slowly coming into light. Am. J Respir. Cell Mal Biol. (2000) 22:520–523.
   PubMed Web of Science ®Google Scholar
• •A thorough review on molecular pathways of pulmonary fibrosis.
   Google Scholar
• MISHRA A, DOYLE NA, MARTIN WJ II: Bleomycin-mediated pulmonary toxicity. Evidence for a p53-mediated response. Am. J Respir. Cell Mal Biol. (2000) 22:543–549.
   Google Scholar
• SCHEULE RK, PERKINS RC, HAMILTON R, HOLIAN A: Bleomycin stimulation of cytokine secretion by the human alveolar macrophage. Am. J. Physiol (1992) 262:L386–L391.
   PubMed Web of Science ®Google Scholar
• PHAN SH, KUNKEL SL: Lung cytokine production in bleomycin-induced pulmonary fibrosis. Exp. Lung Res. (1992) 18:29–43.
   PubMed Web of Science ®Google Scholar
• PIGUET PF, COLLART MA, GRAU GE, KAPANCI Y, VASSALLI P: Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J. Exp. Med. (1989) 170:655–663.
   PubMed Web of Science ®Google Scholar
• PIGUET PF, VESIN C, GRAU GE, THOMPSON RP: Interleukin 1 receptor antagonist (ILl-ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine (1993) 5:57–60.
   PubMed Web of Science ®Google Scholar
• SCHMIDT JA, MIZEL SB, COHEN D, GREEN I: Interleukin-1, a potential regulator of fibroblast proliferation. Immunol (1982) 128:2177–2182.
   Web of Science ®Google Scholar
• MIYAZAKI Y, ARAKI K, VESIN C et al.: Expression of a tumor necrosis factor-a transgene in murine lung causes lymphocytic and fibrosing alveolitis. j Clin. Invest. (1995) 96:250–259.
   PubMed Web of Science ®Google Scholar
• SIME PJ, MARR RA, GLAUDIE D et al.: Transfer of tumor necrosis factor-a to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-P1 and myofibroblast. Am. J. Pathol (1998) 153:825–832.
   PubMed Web of Science ®Google Scholar
• PIGUET PF, KAUFMAN S, BARAZZONE C, MULLER M, RYFFEL B, EUGSTER HP: Resistance of TNF/LTa double deficient mice to bleomycin-induced fibrosis. Int. J. Exp. Path. (1997) 78:43–48.
   PubMed Web of Science ®Google Scholar
• KUROKI M, NOGUCHI Y, SHIMONO M et al.: Repression of bleomycin-induced pneumopathy by TNF. Immunol (2003) 170:567–574.
   Web of Science ®Google Scholar
• JORDANA M, RICHARDS C, IRVING LB, GAULDIE J: Spontaneous in vitro release of alveolar-macrophage cytokines after the intratracheal instillation of bleomycin in rats. Am. Rev. Respir. Dis. (1988) 137:1135–1140.
   PubMed Web of Science ®Google Scholar
• YOSHIDA M, SAKUMA J, HAYASHI S et al: A histologically distinctive interstitial pneumonia induced by overexpression of the interleukin-6, transforming growth factor-31, or platelet-derived growth factor B gene. Proc. Nati Acad. Sci. USA (1995) 92:9570–9574.
   PubMed Web of Science ®Google Scholar
• TAKAMIZAWA A, KOYAMA S, SATO E et al.: Bleomycin stimulates lung fibroblasts to release neutrophils and monocyte chemotaxtic activity. J Immunol (1999) 162:6200–6208.
   PubMed Web of Science ®Google Scholar
• SMITH RE, STRIETER RM, PHAN SM, KUNKEL SL: C-C chemokines: novel mediators of the profibrotic inflammatory response to bleomycin challenge. Am. J. Respir. Cell Mol. Biol. (1996) 15:693–702.
   PubMed Web of Science ®Google Scholar
• KEANE MP, BELPERIO JA, MOORE TA et aL: Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis. J. Immunol. (1999) 162:5511–5518.
   PubMed Web of Science ®Google Scholar
• KEANE MP, BELPERIO JA, ARENBERG DA et al.: IFNI/ inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J. Immunol. (1999) 163:5686–5692.
   PubMed Web of Science ®Google Scholar
• TUNER-WARWICK M: Precapillary systemic-pulmonary anastomoses. Thorax (1963) 18:225.
   PubMedGoogle Scholar
• PEAO MN, AGUAS AP, DE SA CM, GRANDE NR: Neoformation of blood vessels in association with rat lung fibrosis induced by bleomycin. Anat. Rec. (1994) 238:57–67.
   PubMedGoogle Scholar
• OWEN C: Chemokine receptors in airway disease: which receptors to target? Pulm. Pharmacol. Ther. (2001) 14:193–202.
   Web of Science ®Google Scholar
• SANTANA A, SAXENA B, NOBLE NA, GOLD LI, MARSHALL BC: Increased expression of transforming growth factor 13 isoforms32, 33) in bleomycin-induced pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. (1995) 13:34–44.
   PubMed Web of Science ®Google Scholar
• ZHANG K, FLANDERS KC, PHAN SH: Cellular localization of transforming growth factor-3 expression in bleomycin-induced pulmonary fibrosis. Am. J. Pathol. (1995) 147:352–361.
   PubMed Web of Science ®Google Scholar
• POSTLETHWAITE AE, KESKI-OJA J, MOSES HL, KANG AH: Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor 11 J. Exp. Med. (1987) 165:251–256.
   PubMed Web of Science ®Google Scholar
• PHAN SH, GHARAEE-KERMANI M, WOLBER F, RYAN US: Stimulation of rat endothelial cell transforming growth factor-3 production by bleomycin. Clin. Invest. (1991) 87:148–154.
   Google Scholar
• GIRI SN, HYDE DM, HOLLINGER MA: Effect of antibody to transforming growth factor 13 on bleomycin-induced accumulation of lung collagen in mice. Thorax (1993) 48:959–966.
   PubMed Web of Science ®Google Scholar
• ZHAO J, SHI W, WANG YL et cd.: Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am. J. Physiol. Lung Cell Mol. Physiol. (2002) 282:L585–L593.
   Google Scholar
• HOMMA S, NAGAOKA I, ABE H et al.: Localization of platelet-derived growth factor and insulin-like growth factor-1 in the fibrotic lung. Am. J. Respir. Crit. Care Med. (1995) 152:2084–2089.
   PubMed Web of Science ®Google Scholar
• NICI L, CALABRESI P: Amifostine modulation of bleomycin-induced lung injury in rodents. Semin. Oncol. (1999) 26:28–33.
   PubMed Web of Science ®Google Scholar
• HERMAN EH, HASINOFF BB, ZHANG J et al.: Morphologic and morphometric evaluation of the effect of ICRF-187 on bleomycin-induced pulmonary toxicity. Toxicology (1995) 98:163–175.
   PubMed Web of Science ®Google Scholar
• LINKS M, LEWIS C: Chemoprotectants. A review of their clinical pharmacology and therapeutic efficacy. Drugs (1999) 57:293–308.
   Google Scholar
• LOSSOS IS, OR R, GOLDSTEIN RH, CONNER MW, BREUER R: Amelioration of bleomycin-induced pulmonary injury by cyclosporin A. Exp. Lung Res. (1996) 22:337–349.
   PubMed Web of Science ®Google Scholar
• ENTZIAN P, ZÄHRINGER U, SCHLAAK M, GERLACH C, GALLE J, ZABEL P: Comparative study on effects of pentoxifylline, prednisolone and colchicines in experimental alveolitis. Int. J. Immunopharmacol. (1998) 20:723–735.
   PubMed Web of Science ®Google Scholar
• KREMER S, BREUER R, LOSSOS IS et al.: Effect of immunomodulators on bleomycin-induced lung injury. Respiration (1999) 66:455–462.
   PubMed Web of Science ®Google Scholar
• GOFFIN J, KREISMAN H, SANDOR V: Bleomycin-induced lung toxicity and pentoxifylline. j Clin. Oncol. (2001) 19:597–598.
   PubMed Web of Science ®Google Scholar
• PIGUET PF, VESIN C: Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur. Respir. J. (1994) 7:5 15–51 8.
   Google Scholar
• KUWANO K, KUNITAKE R, MAEYAMA T et al.: Attenuation of bleomycin-induced pneumopathy in mice by a caspase inhibitor. Am. J. Physiol. Lung Cell Mol. Physiol. (2001) 280:316–325.
   PubMed Web of Science ®Google Scholar
• GURUJEYALAKSHIMI G, GIRT SN: Molecular mechanisms of antifibrotic effect of interferon yin bleomycin-mouse model of lung fibrosis: downregulation of TGF-P and procollagen I and III gene expression. E. Lung Res. (1995) 21:791–808.
   PubMed Web of Science ®Google Scholar
• NAKAO A, FUJII M, MATSUMURA R et al.: Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J. Clin. Invest. (1999) 104:5–11.
   PubMed Web of Science ®Google Scholar
• HUANG M, SHARMA S, ZHU LX et al.: IL-7 inhibits fibroblast TGF-P production and signaling in pulmonary fibrosis. Clin. Invest. (2002) 109(7):931–937.
   Google Scholar
• ZIESCHE R, HOFBAUER E, WITTMANN K, PETKOV V, BLOCK LH: A preliminary study of long-term treatment with interferon ylb and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl. J. Med. (1999) 341:1264–1269.
   PubMed Web of Science ®Google Scholar